CLARET ASSET MANAGEMENT Corp lowered its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.3% during the third quarter, Holdings Channel reports. The institutional investor owned 7,056 shares of the medical research company’s stock after selling 94 shares during the period. CLARET ASSET MANAGEMENT Corp’s holdings in Amgen were worth $1,365,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in AMGN. Nuveen Asset Management LLC boosted its holdings in Amgen by 1,334.9% during the second quarter. Nuveen Asset Management LLC now owns 4,942,807 shares of the medical research company’s stock worth $910,860,000 after buying an additional 4,598,329 shares in the last quarter. Thoroughbred Financial Services LLC boosted its holdings in Amgen by 19,447.3% during the second quarter. Thoroughbred Financial Services LLC now owns 1,805,392 shares of the medical research company’s stock worth $180,539,000 after buying an additional 1,796,156 shares in the last quarter. BlackRock Inc. boosted its holdings in Amgen by 3.4% during the second quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock worth $8,793,346,000 after buying an additional 1,585,911 shares in the last quarter. Ruffer LLP purchased a new stake in shares of Amgen in the second quarter valued at about $192,788,000. Finally, Beutel Goodman & Co Ltd. lifted its holdings in shares of Amgen by 50.5% in the second quarter. Beutel Goodman & Co Ltd. now owns 1,100,511 shares of the medical research company’s stock valued at $154,859,000 after purchasing an additional 369,142 shares in the last quarter. 76.24% of the stock is currently owned by hedge funds and other institutional investors.
In other news, SVP Cynthia M. Patton sold 13,426 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $208.07, for a total value of $2,793,547.82. Following the completion of the transaction, the senior vice president now owns 32,648 shares of the company’s stock, valued at $6,793,069.36. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $206.70, for a total transaction of $413,400.00. Following the completion of the transaction, the director now directly owns 16,336 shares of the company’s stock, valued at approximately $3,376,651.20. The disclosure for this sale can be found here. In the last three months, insiders sold 17,851 shares of company stock valued at $3,671,900. Company insiders own 0.25% of the company’s stock.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, beating analysts’ consensus estimates of $3.58 by $0.39. The business had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The company’s revenue was down 3.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.83 earnings per share. Sell-side analysts expect that Amgen, Inc. will post 14.31 EPS for the current fiscal year.
Several brokerages have issued reports on AMGN. Credit Suisse Group reaffirmed an “outperform” rating and issued a $225.00 price target (up previously from $202.00) on shares of Amgen in a report on Friday, August 16th. Wells Fargo & Co reaffirmed a “market perform” rating and issued a $220.00 price target (up previously from $202.00) on shares of Amgen in a report on Tuesday, August 27th. They noted that the move was a valuation call. Evercore ISI reaffirmed a “hold” rating on shares of Amgen in a report on Sunday, August 11th. Leerink Swann set a $189.00 price target on shares of Amgen and gave the company a “hold” rating in a report on Monday, September 30th. Finally, Oppenheimer set a $240.00 price target on shares of Amgen and gave the company a “buy” rating in a report on Monday, September 9th. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $217.41.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.